Shopping Cart
Remove All
Your shopping cart is currently empty
HPK1-IN-65
Catalog No. T214255 Copy Product Info
🥰Excellent
HPK1-IN-65 is a selective, orally active HPK1 inhibitor with an IC50 value of less than 5 nM, demonstrating 1257-fold selectivity over the MAP4K kinase family member GLK. It inhibits pSLP76 phosphorylation with an IC50 of 92.3 nM and stimulates IL-2 production with an EC50 of 398 nM. Additionally, HPK1-IN-65 suppresses the phosphorylation of the TCR-induced SLP76Ser376 site in a dose-dependent manner. This compound is also applicable in colon cancer research.
HPK1-IN-65
Copy Product Info🥰Excellent
Catalog No. T214255
HPK1-IN-65 is a selective, orally active HPK1 inhibitor with an IC50 value of less than 5 nM, demonstrating 1257-fold selectivity over the MAP4K kinase family member GLK. It inhibits pSLP76 phosphorylation with an IC50 of 92.3 nM and stimulates IL-2 production with an EC50 of 398 nM. Additionally, HPK1-IN-65 suppresses the phosphorylation of the TCR-induced SLP76Ser376 site in a dose-dependent manner. This compound is also applicable in colon cancer research.
HPK1-IN-65
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | HPK1-IN-65 is a selective, orally active HPK1 inhibitor with an IC50 value of less than 5 nM, demonstrating 1257-fold selectivity over the MAP4K kinase family member GLK. It inhibits pSLP76 phosphorylation with an IC50 of 92.3 nM and stimulates IL-2 production with an EC50 of 398 nM. Additionally, HPK1-IN-65 suppresses the phosphorylation of the TCR-induced SLP76Ser376 site in a dose-dependent manner. This compound is also applicable in colon cancer research. |
| Targets&IC50 | HPK1:<5 nM |
| In vitro | HPK1-IN-65 (compound 34) reduces pSLP76 levels in Jurkat cells in a dose-dependent manner, with an IC50 of 92.3 nM. It stimulates IL-2 production with an EC50 of 398 nM, enhancing the activation effect up to 3.59-fold. Additionally, HPK1-IN-65 exhibits antiproliferative effects on Jurkat cells and shows selectivity for MAP4K2, MAP4K3, MAP4K4, MAP4K5, and MAP4K6. |
| In vivo | HPK1-IN-65 (compound 34), administered orally at a dose of 60 mg/kg once daily for 14 consecutive days, demonstrates potent antitumor activity in a CT-26 syngeneic tumor model using female BALB/c mice aged six weeks. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy HPK1-IN-65 | purchase HPK1-IN-65 | HPK1-IN-65 cost | order HPK1-IN-65 | HPK1-IN-65 in vivo | HPK1-IN-65 in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.